Hindié E, Mellière D, Jeanguillaume C, Perlemuter L, Chéhadé F, Galle P
Department of Nuclear Medicine, Henri Mondor University Hospital, Créteil, France.
J Nucl Med. 1998 Jun;39(6):1100-5.
Technetium-99m-sestamibi represents an important advance in the scintigraphic location of parathyroid neoplasms. However, the optimal procedure for 99mTc-sestamibi parathyroid scanning has not been defined. The first objective of this work was to optimize the technical aspects of subtraction scanning, using simultaneous double-window recording of 99mTc-sestamibi and 1231 instead of successive image recording. The second objective was to compare two protocols for detecting abnormal parathyroid glands: subtraction scanning and single-tracer double-phase scanning.
Thirty patients referred for first surgery of primary hyperparathyroidism had both subtraction scanning and double-phase scanning in the same imaging session. Images of 99mTc-sestamibi and 123I were recorded simultaneously in nonoverlapping windows and then subtracted. For double-phase scanning, images of 99mTc-sestamibi, acquired 15 min and 120 min after tracer injection, were visually compared. Surgery disclosed a solitary adenoma in 27 patients, bilateral adenomata in 2 patients and 3 hyperplastic glands in the last patient. No patient had persistent hypercalcemia.
Preoperative 99mTc-sestamibi/123I subtraction scanning located 25 of 27 solitary adenomas, the bilateral adenomata and 3 of 3 hyperplastic glands. The overall sensitivity for enlarged parathyroids was 94%, and the false-positive image rate was 3%. The 99mTc-sestamibi single-tracer technique located 22 of 27 solitary adenomas, the bilateral adenomata and 1 of 3 hyperplastic glands. Overall sensitivity was 79% and the false-positive image rate was 10%. The gamma camera imaging time was 30 min for the subtraction technique and 50 min for the single-tracer double-phase study. An ectopic adenoma in the sheath of the right carotid artery was detected by both techniques.
These results, together with other data in the literature, indicate that 99mTc-sestamibi/123I subtraction imaging is accurate in locating enlarged parathyroids. Classical difficulties of this technique (motion artifacts and prolonged immobilization) were avoided by using simultaneous recording of the two isotopes. In this series subtraction imaging was more rapid and more sensitive (p < 0.04) than the single-tracer technique.
锝-99m-甲氧基异丁基异腈代表甲状旁腺肿瘤闪烁显像定位方面的一项重要进展。然而,99mTc-甲氧基异丁基异腈甲状旁腺扫描的最佳程序尚未确定。这项工作的首要目标是优化减影扫描的技术环节,采用99mTc-甲氧基异丁基异腈和123I的同步双窗口记录而非连续图像记录。第二个目标是比较两种检测异常甲状旁腺的方案:减影扫描和单示踪剂双期扫描。
30例因原发性甲状旁腺功能亢进接受首次手术的患者在同一次成像检查中同时进行了减影扫描和双期扫描。99mTc-甲氧基异丁基异腈和123I的图像在不重叠的窗口中同时记录,然后进行相减。对于双期扫描,比较注射示踪剂后15分钟和120分钟采集的99mTc-甲氧基异丁基异腈图像。手术发现27例患者为单发腺瘤,2例为双侧腺瘤,最后1例为3个增生性腺瘤。无患者持续存在高钙血症。
术前99mTc-甲氧基异丁基异腈/123I减影扫描定位出27个单发腺瘤中的25个、双侧腺瘤以及3个增生性腺瘤中的3个。甲状旁腺增大的总体敏感性为94%,假阳性图像率为3%。99mTc-甲氧基异丁基异腈单示踪剂技术定位出27个单发腺瘤中的22个、双侧腺瘤以及3个增生性腺瘤中的1个。总体敏感性为79%,假阳性图像率为10%。减影技术的γ相机成像时间为30分钟,单示踪剂双期研究为50分钟。两种技术均检测到右侧颈动脉鞘内的异位腺瘤。
这些结果以及文献中的其他数据表明,99mTc-甲氧基异丁基异腈/123I减影成像在定位增大的甲状旁腺方面是准确的。通过同时记录两种同位素避免了该技术的经典难题(运动伪影和长时间固定)。在本系列研究中,减影成像比单示踪剂技术更快速、更敏感(p < 0.04)。